Welcome to Webinar for applicants to NOT-RM-20-015

Wednesday May 6, 2020 4:00PM EDT

All participants will be muted.

Ask questions during the webinar in the chat or by emailing cfcovid19@od.nih.gov

NB: These slides can be found at https://commonfund.nih.gov/covid19 after the webinar.
• NIH Common Fund
• NOT-RM-20-015 NOSI
• Some of our FAQs
• Questions from audience
December 9, 2006: Congress unanimously passes a reauthorization bill affirming importance of NIH and its vital role in advancing biomedical research to improve the health of the Nation

2004: NIH Roadmap is launched

Establishes the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) within Office of the Director and the NIH Common Fund to provide a dedicated source of funding to enable goal driven trans-NIH research
NOT-RM-20-015

Notice of Special Interest (NOSI):
Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

Related Announcements:
• PA-20-135 Emergency Competitive Revision to Existing NIH Grants and Cooperative Agreements (Emergency Supplement - Clinical Trial Optional)
• NOT-RM-20-016 Notice of the Common Fund’s Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Grants and Cooperative Agreements (Emergency Supplement - Clinical Trial Optional)"
NOT-RM-20-015 Key Dates

Release Date: April 27, 2020

Expiration Date: June 20, 2020

Application due date: June 19, 2020, 5PM local time

As always, we encourage you to apply before the due date.
The Office of Strategic Coordination (OSC), which manages the Common Fund, is issuing this Notice of Special Interest (NOSI) to stimulate innovative research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the disease it causes, Coronavirus Disease 2019 (COVID-19).

- OSC seeks new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally.
- The funding for this supplement is provided from the Coronavirus Aid, Relief, and Economic Security (CARES) Act, 2020.
- OSC is therefore offering Emergency Competitive Revisions to active Common Fund grants and cooperative agreements addressing the research objectives described below.
Background

The present COVID-19 pandemic necessitates a rapid response to understand the transmission, pathology, and morbidity of SARS-CoV-2 infection informed by basic biological studies to clinical research.

The Common Fund supports innovative research projects covering the full spectrum of biomedical research to shift established scientific paradigms, advance technologies, and generate impactful discoveries.

OSC plans to leverage existing projects to rapidly provide greater insights into COVID-19 with the goal of addressing the current national emergency.
Research Objectives

In order to rapidly improve the understanding, diagnosis, and treatment of COVID-19, OSC is encouraging the submission of innovative applications for Emergency Competitive Revisions to active Common Fund grants and cooperative agreements.

- Innovation may be technological or conceptual.
- Any relevant area of innovative research is welcome, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics.
Eligibility

• Applicant must be active grantees of a Common Fund award as indicated on the Notice of Award.

• Eligible activity codes are limited to the following mechanisms: D43, DP2, DP5, DP7, R01, R24, R25, R35, U01, U18, U19, U24, U2C, U2R, U42, U54, UG3, UH2, UH3, and UM1.

• Other transaction (OT) awards are not eligible.
Application and Submission Information

Applications in response to this NOSI must be submitted using the following targeted funding opportunity:

- **PA-20-135** Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional), which is intended to provide funds for NIH grantees applying to expand the scope of their active grant.

- The funding instrument, or activity code, will be the same as the parent award.

- Recipients may apply for work that is related to your funded project, whether within the scope or outside of the scope of the current project, regardless of the time remaining on the current project.

- Grants currently in a no-cost extension are eligible to apply.
Application and Submission Information

Please note: NOT-RM-20-015 is specific for PA-20-135.

NIH grantees seeking additional funds for research responsive to the SARS-CoV-2/COVID-19 outbreak that falls within the scope of an ongoing grant should instead apply for an administrative supplement under NIH PA-18-591, Administrative Supplements to Existing NIH Grants and Cooperative Agreements FOA (https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html).
Application and Submission Information

• All applications must be submitted electronically. When developing applications in response to this NOSI, all instructions in the SF424 (R&R) Application Guide and PA-20-135 must be followed, with the following additions:

• Due Dates – Applications will be accepted on a rolling basis through June 19, 2020, by 5:00 PM local time of applicant organization.

• Requests may be for one year of support only.

• The Research Strategy section of the application is limited to 6 pages.

• A Data Sharing Plan must be included and must describe how the investigators will:
  - Rapidly share data and relevant metadata in a format and through a structure that will allow them to be findable and accessible to others.
  - Support efforts to ensure harmonization of collected covariates and outcomes using existing standard ontologies supported by NIH/NLM.
  - Align and share with national and international COVID-19 related genomics initiatives such as the COVID-19 Host Genetics Initiative (https://www.covid19hg.org/), as appropriate and consistent with achieving the goals of the program.
Application and Submission Information

- Application budgets **should not exceed the annual amount of the current parent award and should reflect the actual needs of the proposed project.** Exceptions will be considered on a case-by-case basis.

- **IMPORTANT:** For funding consideration, all applicants must designate “NOT-RM-20-015” (without quotation marks) in the Agency Routing Identifier field (Box 4b) of the SF424 (R&R) Form.
Review Process

Applications will be evaluated for scientific and technical merit by an appropriate internal review panel convened by OSC staff, in accordance with the review criteria specified in the FOA as well as these additional review criteria:

- **Urgency and significance of research**: How will successful completion of the aims contribute to or complement public health efforts for the control of SARS-CoV-2 infection and related pathogenic processes? Does the proposed research fit within the mission of an emergency response to provide critical expertise, resources or activities?

- **Feasibility of research**: Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Is the emergency time frame feasible for the proposed research? Are the PD/PIs, collaborators, and other researchers well suited and appropriate to carry out the project?

- **Data sharing plan**: Are there timely plans to make results and data findable and accessible to the research community?
Talk to the NIH about your plans before you submit!!

Investigators planning to submit an application in response to the NOSI are strongly encouraged to contact the program officer listed on the Notice of Award for the parent award to discuss whether the proposed project conforms with the policies and procedures of the specific administering Institute or Center. Investigators are also encouraged to contact the program officer listed in the NOSI to discuss the proposed project in the context of the Common Fund interests.
Q: I have a grant, but it is not a Common Fund grant. Can I apply to this NOSI?
A: No, the parent award must be a Common Fund grant. Starting in FY2021, the Common Fund will issue funding opportunities for researchers to develop new research projects. Continue to check our website for updates on future SARS-CoV-2 and COVID-19 research funding opportunities from the NIH Common Fund. We also encourage you to visit the COVID-19 page of information for NIH applicants and recipients of NIH funding to check on NIH funding opportunities that may be appropriate for your research.

Q: My grant, which is not a Common Fund grant, previously received a supplement from the Common Fund. Can that supplement serve as a Common Fund award for eligibility for this NOSI?
A: No, you must have an active Common Fund parent grant to be eligible.
Q: How do I know if my existing grant is a Common Fund grant since it is administered by one of the Institutes or Centers (ICs)?
A: Most Common Fund awards are in response to RFAs starting with an RM code. The awards are generally part of an overarching Common Fund Program listed here: [https://commonfund.nih.gov/initiativeslist](https://commonfund.nih.gov/initiativeslist).

Q: If my Common Fund award is on a No Cost Extension (NCE), am I eligible?
A: Grants currently or soon to be in a no-cost extension are eligible to apply. Please contact the Program Officer on your award to determine whether the administering Institute or Center will allow a competitive revision to an award on a No Cost Extension.

Q: What mechanisms are eligible?
A: D43, DP2, DP5, DP7, R01, R24, R25, R35, U01, U18, U19, U24, U2C, U2R, U42, U54, UG3, UH2, UH3, and UM1. Contracts and Other Transaction awards are **not** eligible.
Q: Will the applicant webinar be posted online afterward?
A: No. A recording of the webinar will not be posted online, but the slide deck will be posted on this website (https://commonfund.nih.gov/covid19). Following the webinar, a list of FAQs will be updated to reflect questions asked during the webinar.

Q: What is the maximum amount of direct costs available for each project?
A: Application budgets are not limited but must reflect the actual needs of the proposed project. In addition, applicants who request $500,000 or more for direct costs (excluding consortium F&A) must receive permission from their Program Officer of the parent award before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs: https://grants.nih.gov/grants/policy/nihgps/HTML5/section_2/2.3.7_policies_affecting_applications.htm#Acceptan. Applications that do not conform to the administering IC’s policies and procedures will not be funded.
Some FAQs:

Q: May I submit more than one application to the PA-20-135?
A: Yes, multiple applications per applicant are allowed; however, each application must be scientifically distinct.

Q: May I apply to this NOSI in addition to the COVID-19-related funding opportunities from the other NIH Institutes and Centers (ICs)?
A: Yes, applicants can apply to multiple COVID-19 related funding opportunities as long as the projects are relevant to the areas of interest in the cited Notice of Special Interest (NOSI). For a list of funding opportunities from multiple NIH Institutes, Centers, and Offices – including the NIH Common Fund - please visit the COVID-19 page of information for NIH applicants and recipients of NIH funding.

Q: Do the flexibilities for late application submission apply to this NOSI?
A: No, the flexibilities for late application submission listed in NOT-OD-20-082 do not apply to this NOSI. All applications must be received by June 19, 2020 at 5PM.
Some FAQs:

Q: When will applications be reviewed?
A: The review is planned to occur in July 2020.

Q: Will I receive written comments or feedback from the review?
A: No. The review committee will not be able to provide comments or feedback due to the shortened timeline.

Q: What criteria will be used to judge the merit of applications?
A: In addition to the review criteria in PA-20-135, the criteria from NOT-RM-20-015 are:

• **Urgency and significance of research:** How will successful completion of the aims contribute to or complement public health efforts for the control of SARS-CoV-2 infection and related pathogenic processes? Does the proposed research fit within the mission of an emergency response to provide critical expertise, resources or activities?

• **Feasibility of research:** Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Is the emergency time frame feasible for the proposed research? Are the PD/PIs, collaborators, and other researchers well suited and appropriate to carry out the project?

• **Data sharing plan:** Are there timely plans to make results and data findable and accessible to the research community?
Some FAQs:

Q: What is the set-aside for this funding opportunity?
A: There is not a set-aside for this program announcement. However, the Common Fund received $30M to be used over five years from the CARES Act to support innovative perspectives and approaches for the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. We plan to use a portion of these funds in FY20 to fund up to 10-20 high impact, emergency competitive revisions/supplements in response to PA-20-135.

Q: May I apply under this NOSI to this to cover unanticipated expenses for my research project that result from COVID-19?
A: No. This NOSI is exclusively for research on COVID-19 and SARSCoV-2. Applications for other purposes will be administratively withdrawn.

Q: When will the competitive revision projects be funded?
A: Projects will be funded in August or September 2020.
Webinar for applicants to NOT-RM-20-015

All participants are muted.

Ask questions during the webinar in the chat or by emailing cfcovid19@od.nih.gov

NB: These slides can be found at https://commonfund.nih.gov/covid19 after the webinar.